

FIG. 1A




FIG. 1B

2/53




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4A




FIG. 4B

5/53




FIG. 5A




FIG. 5B




FIG. 6

7/53




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10

11/53




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B

BioFINDER-2




FIG. 13A

Knight-ADRC




FIG. 13B

Contribution:  Amyloid  Tau




FIG. 14

15/53




FIG. 15A




FIG. 15B

16/53




FIG. 16A





FIG. 16B






FIG. 18A




FIG. 18B

19/53





FIG. 18C




FIG. 19




FIG. 20B

FIG. 20A




FIG. 21A




FIG. 21B

Design	1 st Step	2 nd step
#1	Tau1/HJ8.5/HJ8.7	HJ32.11
#2	Tau1/HJ8.5/HJ8.7/HJ34.8	HJ32.11

FIG. 21C

24/53




FIG. 22A





FIG. 22B

25/53

Design	1 st Step	2 nd step
#1	Tau1/HJ8.5/HJ8.7	HJ32.11
#2	Tau1/HJ8.5/HJ8.7/HJ34.8	HJ32.11

FIG. 22C



27/53





FIG. 24A



MTBR243 maintains the discrimination power to identify tau pathology even in Amyloid-positive sub-group

FIG. 24B

28/53




FIG. 24C

29/53




FIG. 25

30/53




FIG. 26A




FIG. 26B

31/53




FIG. 27

32/53




FIG. 28

33/53




FIG. 29

34/53




FIG. 30A






FIG. 30B




R.LQTAPVPMPLKN.- [243-255N]

FIG. 31A




R.LQTAPVPMPLKN.- [243-255N-deamidation]

FIG. 31B



-.LQTAPVPMPLKLVK.- [243-257K]


FIG. 32A



-.LQTAPVPMPLKLVK.- [243-257K @255N-deamidation]


FIG. 32B

37/53




-.LQTAPVMPMPD.- [243-252D]

FIG. 33A




-.LQTAPVMPMPDLKNVKS.- [243-258S @255N-deamidation]

FIG. 33B



-.LQTAPVPMPDL.- [243-253L]


FIG. 34A



-.LQTAPVPMPDLK.- [243-254K @244-deamidation]


FIG. 34B

39/53



R.LQTAPVMPDLK.N [MTBR243-254 (ordinal MTBR243)]


FIG. 35A



-.LQTAPVMPDLKNV.- [MTBR243-256V]


FIG. 35B

40/53



LQTAPVPMPDLKNV [243-256V]

FIG. 36A



LQTAPVPMPDLKdNV [243-dN-256V]

FIG. 36B

FIG. 37A




FIG. 37B

FIG. 37C




FIG. 37D

FIG. 37E




FIG. 37F

44/53




FIG. 38

45/53





FIG. 39

46/53

CSF vs Plasma MTBR-tau243

Number of XY Pairs 18

CSF vs Plasma_MTBR-tau243-256dN translation (>LOD)



5 Amyloid-negative ppts out of total 15 ppts exhibited >LOD

13 Amyloid-positive ppts out of total 20 exhibited >LOD

FIG. 40A

Tau-PET vs "Plasma" MTBR-tau243-256dN

Number of XY Pairs 18

tau-PET vs Plasma_MTBR-tau243-256dN translation (>LOD)




FIG. 40B

Tau-PET vs “CSF” MTBR-tau243




FIG. 40C

48/53




FIG. 41

49/53




FIG. 42

50/53




FIG 43A




FIG 43B




FIG 43A

52/53




FIG 44

53/53




FIG 45